Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  














Pirisudanol






العربية
Español
Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Pirisudanol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-(dimethylamino)ethyl[5-hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridinyl]methylbutanedioate

CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.046.887 Edit this at Wikidata
Chemical and physical data
FormulaC16H24N2O6
Molar mass340.376 g·mol−1
3D model (JSmol)
  • CC1=NC=C(C(=C1O)CO)COC(=O)CCC(=O)OCCN(C)C

  • InChI=1S/C16H24N2O6/c1-11-16(22)13(9-19)12(8-17-11)10-24-15(21)5-4-14(20)23-7-6-18(2)3/h8,19,22H,4-7,9-10H2,1-3H3

  • Key:KTOAWCPDBUCJED-UHFFFAOYSA-N

  (verify)

Pirisudanol (Mentis, Menthen, Mentium, Nadex, Nadexen, Nadexon, Pridana, Stivane), also known as pyrisuccideanol, is the succinic acid esterofpyridoxine (a form of vitamin B6) and of deanol (DMAE).[1] It has been used in Europe in the treatment of mild cognitive impairment as well as fatigue and depression.[1][2][3][4][5]

See also[edit]

References[edit]

  1. ^ a b "Psycho-Babble Medication Thread 69493".
  • ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  • ^ Bathien N, Willer JC, Hugelin A (1976). "[Effect of psychotropic drugs on physiological variations and psychometric scores during attention]". L'Encéphale (in French). 2 (1): 55–60. PMID 1261486.
  • ^ Murphy JE (1981). "An evaluation of pyrisuccideanol maleate (Nadex) in the treatment of mild to moderate depression in patients aged 55 years and over, presenting in general practice". The Journal of International Medical Research. 9 (5): 330–7. doi:10.1177/030006058100900506. PMID 7297757. S2CID 30526982.
  • ^ Zmorski T (September 1983). "[Experience with Nadex in an ambulatory psychiatric practice]". Therapeutische Umschau. Revue Thérapeutique (in German). 40 (9): 817–20. PMID 6138876.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Pirisudanol&oldid=1092286309"

    Categories: 
    Cholinergics
    Pyridines
    Phenols
    Primary alcohols
    Succinate esters
    Prodrugs
    Nootropics
    Antidepressants
    Nervous system drug stubs
    Hidden categories: 
    CS1 French-language sources (fr)
    CS1 German-language sources (de)
    Articles with short description
    Short description matches Wikidata
    Drugs with non-standard legal status
    ECHA InfoCard ID from Wikidata
    Articles without EBI source
    Chemical pages without DrugBank identifier
    All stub articles
     



    This page was last edited on 9 June 2022, at 10:04 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki